Nanocrystal Technology, Drug Delivery and Clinical Applications

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2008 Nov 11

PMID 18990939

Citations 195

Authors

Jens-Uwe A H Junghanns

Rainer H Muller

Affiliations

Soon will be listed here.

Abstract

Nanotechnology will affect our lives tremendously over the next decade in very different fields, including medicine and pharmacy. Transfer of materials into the nanodimension changes their physical properties which were used in pharmaceutics to develop a new innovative formulation principle for poorly soluble drugs: the drug nanocrystals. The drug nanocrystals do not belong to the future; the first products are already on the market. The industrially relevant production technologies, pearl milling and high pressure homogenization, are reviewed. The physics behind the drug nanocrystals and changes of their physical properties are discussed. The marketed products are presented and the special physical effects ofnanocrystals explained which are utilized in each market product. Examples of products in the development pipelines (clinical phases) are presented and the benefits for in vivo administration of drug nanocrystals are summarized in an overview.

Citing Articles

Recent Advances in Antiviral Drug Delivery Strategies.

Rana D, Prajapati A, Karunakaran B, Vora L, Benival D, Jindal A AAPS PharmSciTech. 2025; 26(3):73.

PMID: 40038154 DOI: 10.1208/s12249-025-03053-3.

Pharmaceutical technological trends containing flavonoids: a patent review.

Oliveira A, Santos A, Nascimento Junior J, Santana Junior C, Brito J, Dos Santos J Future Med Chem. 2025; 17(3):363-379.

PMID: 39835701 PMC: 11792795. DOI: 10.1080/17568919.2025.2453408.

Transforming Medicine: Cutting-Edge Applications of Nanoscale Materials in Drug Delivery.

Tenchov R, Hughes K, Ganesan M, Iyer K, Ralhan K, Lotti Diaz L ACS Nano. 2025; 19(4):4011-4038.

PMID: 39823199 PMC: 11803921. DOI: 10.1021/acsnano.4c09566.

Strategies to Enhance Nanocrystal Formulations for Overcoming Physiological Barriers Across Diverse Routes of Administration.

Yanamadala Y, Muthumula C, Khare S, Gokulan K Int J Nanomedicine. 2025; 20():367-402.

PMID: 39816376 PMC: 11733173. DOI: 10.2147/IJN.S494224.

Nanotherapeutics in Kidney Disease: Innovations, Challenges, and Future Directions.

Roointan A, Xu R, Corrie S, Hagemeyer C, Alt K J Am Soc Nephrol. 2024; 36(3):500-518.

PMID: 39705082 PMC: 11888965. DOI: 10.1681/ASN.0000000608.

References

. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001; 357(9260):905-10. View

Sehgal S . Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998; 31(5):335-40. DOI: 10.1016/s0009-9120(98)00045-9. View

Tunick M, Van Hekken D, Cooke P, Malin E . Transmission electron microscopy of mozzarella cheeses made from microfluidized milk. J Agric Food Chem. 2002; 50(1):99-103. DOI: 10.1021/jf010633c. View

Hancock B, Parks M . What is the true solubility advantage for amorphous pharmaceuticals?. Pharm Res. 2000; 17(4):397-404. DOI: 10.1023/a:1007516718048. View

Shackleford D, Faassen W, Houwing N, Lass H, Edwards G, Porter C . Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs. J Pharmacol Exp Ther. 2003; 306(3):925-33. DOI: 10.1124/jpet.103.052522. View

Bleich J, Muller B . Production of drug loaded microparticles by the use of supercritical gases with the aerosol solvent extraction system (ASES) process. J Microencapsul. 1996; 13(2):131-9. DOI: 10.3109/02652049609052902. View

Bhol K, Schechter P . Topical nanocrystalline silver cream suppresses inflammatory cytokines and induces apoptosis of inflammatory cells in a murine model of allergic contact dermatitis. Br J Dermatol. 2005; 152(6):1235-42. DOI: 10.1111/j.1365-2133.2005.06575.x. View

Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K . The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm. 2004; 285(1-2):135-46. DOI: 10.1016/j.ijpharm.2004.08.001. View

Bhol K, Alroy J, Schechter P . Anti-inflammatory effect of topical nanocrystalline silver cream on allergic contact dermatitis in a guinea pig model. Clin Exp Dermatol. 2004; 29(3):282-7. DOI: 10.1111/j.1365-2230.2004.01515.x. View

10.

Merkle . Biotechnology as a route to nanotechnology . Trends Biotechnol. 1999; 17(7):271-4. DOI: 10.1016/s0167-7799(99)01335-9. View

11.

Willems L, van der Geest R, De Beule K . Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther. 2001; 26(3):159-69. DOI: 10.1046/j.1365-2710.2001.00338.x. View

12.

Gu C, Grant D . Estimating the relative stability of polymorphs and hydrates from heats of solution and solubility data. J Pharm Sci. 2001; 90(9):1277-87. DOI: 10.1002/jps.1080. View

13.

Lee S, Nam K, Kim M, Jun S, Park J, Woo J . Preparation and characterization of solid dispersions of itraconazole by using aerosol solvent extraction system for improvement in drug solubility and bioavailability. Arch Pharm Res. 2005; 28(7):866-74. DOI: 10.1007/BF02977355. View

14.

Kreuter J, Alyautdin R, Kharkevich D, Ivanov A . Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 1995; 674(1):171-4. DOI: 10.1016/0006-8993(95)00023-j. View

15.

Merisko-Liversidge E, Liversidge G, Cooper E . Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci. 2003; 18(2):113-20. DOI: 10.1016/s0928-0987(02)00251-8. View

16.

Muller R, Jacobs C, Kayser O . Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001; 47(1):3-19. DOI: 10.1016/s0169-409x(00)00118-6. View

17.

Castelvetro V, De Vita C . Nanostructured hybrid materials from aqueous polymer dispersions. Adv Colloid Interface Sci. 2004; 108-109:167-85. DOI: 10.1016/j.cis.2003.10.017. View